Sorokac Kubolkova Alena, Varga Gabriel, Benovska Miroslava, Kovacova Lenka, Fedorko Michal
Department of Urology, University Hospital Brno, Brno, Czech Republic.
Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024 Sep 27. doi: 10.5507/bp.2024.028.
Prostate cancer (PC) is one of the most frequently diagnosed non-skin solid cancers and is a leading cause of cancer-related death and the incidence increasing. Early diagnosis of the disease improves the outcomes. There is an urgent need for new biomarkers with greater discriminative precision for diagnosis, risk-stratification and treatment. The aim of our study was to evaluate the diagnostic and prognostic potential of Fetuin-A and LRG1 in patients with PC.
Serum levels of Fetuin-A and LRG1 were compared in patients with PC (n=46), a control group 1 including young, healthy subjects (n=26) and control group 2 including patients with negative prostate biopsy (n=46). In PC patients, the levels of both biomarkers were compared in subgroups with different tumour characteristics.
We demonstrated a statistically significant higher concentrations of Fetuin-A in PC patients compared to control group 2 (439 mg/L vs. 372 mg/L), P<0.001. No statistically significant difference was found between PC patients and control group 1, nor for LRG1 levels between the three groups. In PC patients, higher serum levels of LRG1 were found in M1 patients compared to M0 (98 mg/L vs. 42 mg/L), P=0.059.
Fetuin-A levels are significantly higher in patients with prostate cancer than in patients without malignancy but LRG1 levels do not differ between patients with PC and controls.
前列腺癌（PC）是最常被诊断出的非皮肤实体癌之一，是癌症相关死亡的主要原因，且发病率不断上升。该疾病的早期诊断可改善预后。迫切需要具有更高鉴别精度的新型生物标志物用于诊断、风险分层和治疗。我们研究的目的是评估胎球蛋白-A（Fetuin-A）和富含亮氨酸α-2糖蛋白1（LRG1）在前列腺癌患者中的诊断和预后潜力。
比较了前列腺癌患者（n = 46）、包括年轻健康受试者的对照组1（n = 26）和包括前列腺活检阴性患者的对照组2（n = 46）的血清Fetuin-A和LRG1水平。在前列腺癌患者中，比较了具有不同肿瘤特征亚组中两种生物标志物的水平。
我们发现，与对照组2相比，前列腺癌患者中Fetuin-A的浓度在统计学上显著更高（439 mg/L对372 mg/L），P<0.001。前列腺癌患者与对照组1之间未发现统计学上的显著差异，三组之间的LRG1水平也无显著差异。在前列腺癌患者中，M1患者的血清LRG1水平高于M0患者（98 mg/L对42 mg/L），P = 0.059。
前列腺癌患者的Fetuin-A水平显著高于无恶性肿瘤的患者，但前列腺癌患者与对照组之间的LRG1水平无差异。
